203 related articles for article (PubMed ID: 32930718)
1. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
Hage C; Salvatori R
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32930718
[TBL] [Abstract][Full Text] [Related]
2. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
4. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
6. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M; Souteiro P; Carvalho D
Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
9. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
Araújo C; Marques O; Almeida R; Santos MJ
Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
11. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
12. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
[TBL] [Abstract][Full Text] [Related]
13. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
Pereira AM
Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
15. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
16. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
17. Long-term outcome of macroprolactinomas.
Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
19. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
20. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
